Bruker at Virtual US HUPO 2021

Abstract:
Computationally, real-time database search in proteomics has been difficult because the time to search and assign a fragment ion spectrum to a peptide sequence can take longer than the rate of acquisition. This is particularly true when the search space is large including PTMs or semi-specific search parameters. Here, using massively parallelized search capabilities on a GPU called PaSER we can effectively perform the database search at the same rate as data acquisition, even under difficult search parameters including PTMs and enyme specificity. Additionally, in this talk we will describe the extended capabilities of the timsTOF Pro in prm-PASEF and dia-PASEF modes.  

Abstract:
Productive biomarker discovery studies are resource-limited requiring complex workflows that operate with trade-offs in throughput, scalability, coverage, and precision. Thus, there is a need for new technological solutions for large-scale proteomic studies. Herein, we describe Proteograph™, a novel platform leveraging the nano-bio interactions of nanoparticles and their distinct biophysicochemical properties in forming protein coronas for deep and unbiased proteomic sampling.

Abstract:
Over 100 million people around the world have tested positive for the beta coronavirus SARS-CoV-2 from late 2019 to February 1st, 2021. COVID-19 has been characterized by elevated mortality with approximately 2.24 million deaths, primarily due to thrombo-inflammatory complications that impair lung perfusion and systemic oxygenation in the most severe cases. Over the same time period we developed a plasma proteomics pipeline using the Evosep One and timsTOF Pro system to explore systemic alterations in numerous injury and disease states. Similarities between COVID-19 and trauma, the number one cause of death for individuals under 45 with approximately 5.8 million annual deaths worldwide, lead to the exploration of a therapeutic intervention that activates the fibrinolytic system.